Comprehensive genomic profiling of brain tumors to provide targeted therapy options and diagnostic certainty for oligodendrogliomas.

被引：0
|
作者：
Albacker, Lee A.
Pavlick, Dean
Ross, Jeffrey S.
Lesser, Glenn Jay
Corona, Robert John
Colman, Howard
Groves, Morris D.
Hsu, Sigmund H.
Chi, Andrew S.
Miller, Vincent A.
Frampton, Garrett Michael
Ramkissoon, Shakti
机构：
[1] Fdn Med Inc, Cambridge, MA USA
[2] SUNY Upstate Med Univ, Syracuse, NY 13210 USA
[3] Wake Forest Baptist Med Ctr, Winston Salem, NC USA
[4] Hunstman Canc Inst, Salt Lake City, UT USA
[5] Texas Oncol, Austin Brain Tumor Ctr, Austin, TX USA
[6] Mischer Neurosci Associates, Houston, TX USA
[7] NYU Langone Med Ctr & Sch Med, New York, NY USA
[8] Fdn Med Inc, Morrisville, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2039
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2039
引用
收藏
页数：1
相关论文
共 41 条
  • [31] Comprehensive genomic profiling of solid tumors for key targeted and immuno-oncology biomarkers using Ion Torrent NGS technology on the Oncomine Comprehensive Assay Plus (OCA Plus)
    Mittal, Vinay
    Kilzer, Jennifer
    Cyanam, Dinesh
    Au-Young, Janice
    Bandla, Santhoshi
    Bee, Gary
    El-Difrawy, Sameh
    Ewing, Aren
    Gottimukkala, Rajesh
    Gupta, Mohit
    Khazanov, Nickolay
    Kraltcheva, Anelia
    Marcovitz, Amir
    Myrand, Scott
    Putler, Rose
    Tseng, Yu-Ting
    Tom, Warren
    Van Loy, Cristina
    Veitch, James
    Williams, Paul
    Wong-Ho, Elaine
    Xie, Huimin
    Yang, Chenchen
    Zang, Zheng
    Sadis, Seth
    CANCER RESEARCH, 2020, 80 (16)
  • [32] Comprehensive Genomic Profiling of Epithelial Ovarian Cancer by Next Generation Sequencing-Based Diagnostic Assay Reveals New Routes to Targeted Therapies EDITORIAL COMMENT
    不详
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2013, 68 (10) : 688 - 689
  • [33] Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy
    Tang, Qi
    Zuo, Wei
    Wan, Chong
    Xiong, Shengwei
    Xu, Chunru
    Yuan, Changwei
    Sun, Qiangqiang
    Zhou, Liqun
    Li, Xuesong
    FRONTIERS IN IMMUNOLOGY, 2023, 13
  • [34] Real-world single institution clinical outcome study of the impact of comprehensive genomic profiling (CGP) on targeted therapy selection and cancer patient survival
    Madhira, B. R. R.
    Dhakal, S.
    Srivastava, N.
    Sweet, J.
    Ross, J. S.
    Basnet, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S398 - S398
  • [35] Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy
    Faber, Erin
    Grosu, Horiana
    Sabir, Sharjeel
    San Lucas, Francis Anthony
    Barkoh, Bedia A.
    Bassett, Roland L.
    Luthra, Rajyalakshmi
    Stewart, John
    Roy-Chowdhuri, Sinchita
    JOURNAL OF CLINICAL PATHOLOGY, 2022, 75 (09) : 612 - 619
  • [36] Comprehensive genomic profiling of primary and metastatic CDH1 mutated classic and pleomorphic invasive lobular breast carcinomas reveals markers of hormonal therapy resistance and opportunities for targeted therapies
    Ross, J. S.
    Gay, L. M.
    Elvin, J. A.
    Suh, J.
    Vergilio, J-A.
    Ramkissoon, S.
    Severson, E.
    Daniel, S.
    Frampton, G. M.
    Fabrizio, D.
    Schrock, A. B.
    Ali, S. M.
    Miller, V. A.
    Stephens, P.
    Chung, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML
    Heckman, Caroline A.
    Kontro, Mika
    Pemovska, Tea
    Eldfors, Samuli
    Edgren, Henrik
    Kulesskiy, Evgeny
    Majumder, Muntasir Mamun
    Karjalainen, Riikka
    Yadav, Bhagwan
    Szwajda, Agnieszka
    Venkata, Naga Poojitha Kota
    Murumagi, Astrid
    Malani, Disha
    Parsons, Alun
    Hintsanen, Petteri
    Almusa, Henrikki
    Marti, Jesus Maria Lopez
    Ellonen, Pekka
    Mattila, Pirkko
    Lepisto, Maija
    Lagstrom, Sonja
    Suvela, Minna
    Mustjoki, Satu
    Saarela, Janna
    Aittokallio, Tero
    Kallioniemi, Olli
    Wennerberg, Krister
    Porkka, Kimmo
    BLOOD, 2012, 120 (21)
  • [38] THE ECONOMIC IMPACT OF EARLY COMPREHENSIVE GENOMIC PROFILING AND TARGETED THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS: REAL WORLD EVIDENCE FROM A BRAZILIAN PRIVATE HEALTHCARE PROVIDER DATABASE
    Brust, L.
    Lemos, G.
    Azevedo, R.
    Silva, M. P.
    Oliveira, F.
    Zingano, F.
    Carniato, R.
    Torres, A.
    VALUE IN HEALTH, 2024, 27 (12) : S135 - S136
  • [39] Molecularly matched therapies identified by comprehensive genomic profiling before the first-line setting to provide alternative treatment outcomes in patients with solid tumors: 1-year follow-up of the prospective FIRST-Dx study.
    Hayashi, Ryuji
    Matsubara, Junichi
    Mukai, Kumi
    Yoshioka, Masahiro
    Kage, Hidenori
    Oda, Katsutoshi
    Ikeda, Sadakatsu
    Ebi, Hiromichi
    Muro, Kei
    Kajiura, Shinya
    Ashida, Reiko
    Kitano, Masayuki
    Muto, Manabu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)
    Mileshkin, L.
    Bochtler, T.
    Pauli, C.
    Duran-Pacheco, G.
    Arslan, C.
    Bigot, F.
    Chalabi, N.
    Cook, N.
    Italiano, A.
    Losa, F.
    Menezes, J.
    Michaud, C.
    Ozguroglu, M.
    Cid, R. A. Pazo
    Ross, J. S.
    Shiu, K. K.
    Stahl, M.
    Thomas, M.
    Moch, H.
    Kraemer, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1254 - S1255
12345